Blue Horseshoe Stocks: CNAT Recap & More

Conatus Pharmaceuticals, Inc. CNAT

We were fairly confident that at least one of the pharma news plays we put forth in yesterday’s premarket report would turn out a promising session, and CNAT definitely rose to the occasion.

We highlighted it, of course, because of a big collaboration and licensing deal for one of the company’s drugs, which adds a quick $50M cash to the books almost immediately, and even more down the road.

After gapping up considerably in the premarket, the stock underwent a dip-and-rip scenario which carried it to a daily low of 4.27 before it pushed its way up to a high of 5.50. That marked a solid intraday upswing of 29% and came on four times the three-month average volume.

ACADIA Pharmaceuticals, Inc. ACAD

ACAD was the other play off of our pharma watchlist that provided us with significant opportunities, which were even bigger than the previously mentioned stock.

We offered an options idea, the ACAD Weekly $28-31 Calls, and all but a couple sets of contracts in that range produced respectable intraday moves.

$28 Calls – Range: .70-1.66 – Max Gain: 137%
$28.50 Calls – Range: .59-1.40 – Max Gain: 137%
$29 Calls – Range: .40-.80 – Max Gain: 100%
$29.50 Calls – Range: .30-.70 – Max Gain: 133%
$30 Calls – Range: .18-.50 – Max Gain: 178%


NIKE, Inc. NKE – Fresh Options Idea

NKE is coming off a post-market earnings beat yesterday, so we want to enter an idea into the logs for this situation.

We’re going to be monitoring the activity in the NKE Weekly $52.50-54 Calls for possible daytrades and/or swing trades into the end of the week.

Extended Watchlist:

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.


ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug.  To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)


Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:

Blue Horseshoe Stocks: Fresh Options Ideas, VAPE Recap & More

Fresh Options Ideas

The markets made a notable upturn following yesterday’s Fed meeting from which we learned that it will be proceeding with caution regarding a potential interest rate hike. The floundering world economy as well as trouble with low inflation domestically were cited as reasons behind the reticence. Despite the note of uncertainty, there is nothing ambiguous about the overall market sentiment at present, which is leading us to formulate some bullish ideas on the options-trading front.


We’ve enjoyed tons of success trading SPY options in the past when we need a close analog of the markets as a whole, so it stands to reason that we call out a new idea for some SPY Calls this morning. We’re going to be paying attention to the SPY Weekly $204-206 Calls.

Apple, Inc. AAPL

AAPL seemed to enjoy a boost in the wake of the US Government’s dismissal of the federal court case which had embroiled the two in recent weeks. After enjoying a steady increases throughout the session, the stock is currently gapping up in the premarket. Our target range here is going to be AAPL Weekly $107-109 Calls.

Ambarella, Inc. AMBA

We flagged AMBA in yesterday’s watchlist and it too produced a bullish session. In addition to being connected with AAPL being a provider of internal hardware for Apple devices, AMBA received an upgrade from analysts at Morgan Stanley. We’ve got a corresponding options idea for this one as well. For this play, we’re looking to the AMBA Weekly $44-46 Calls.

Lulu Lemon Athletica, Inc. LULU

LULU is gapping this morning on the heels of an earnings beat, so we’re going to want to signal some calls here as well. This is another stock whose options chain has provided us with ammunition for extreme gains in the past. We’ll be monitoring the LULU Weekly $62-65.50 Calls.

With everything gapping up in the premarket, we’ll of course be on the lookout for possible dip-and-rip scenarios prior to the execution of any of these ideas.

Vape Holdings, Inc. VAPE
We can officially add VAPE to the list of cannabis-related stocks that we’ve witnessed making appreciable upswings this week. We added it to yesterday’s morning report as another pot-play to keep an eye on, and we’re immediately rewarded with a solid opportunity for some single-session gains.

VAPE traded in a range from .0106 to .017 on the day, giving traders the chance at profits of up to 60% The move came in conjunction with the announcement of another round of debt restructuring and consolidation (>>View PR).

We’ve added new cannabis candidates to our radar each day this week, and we’ll repeat that again today, pinning CANL and MCOA to our watchlist.

Extended Watchlist:

Blue Horseshoe Stocks: MAXD Recap, Cannabis Stocks & More

Max Sound Corp. MAXD
A huge standout from Thursday’s session was MAXD, which we tagged as a bottom-bouncer in our premarket report. The stock had been mostly trading sideways over the preceding couple of months, so our alert definitely came at the proper time.

From its daily low of .0033 right at the outset, the stock continually pushed the envelope for a vast majority of the session, eventually reaching the zenith at an impressive .007. That represented an intraday gain opportunity of up to 112% with heavy volume, on the order of more than three times the monthly average.

We’ll continue to track MAXD, looking for the stock continue building a higher base level of support in coming sessions.

United Cannabis Corp. CNAB

We’ve been monitoring the cannabis space more closely over the past couple of weeks, since a big development from the labs at GW Pharma (GWPH) sent shockwaves through the investment community and began to drive heavier interest back to marijuana related stocks.

We’re still seeing those effects reverberating down to several of these ‘pot-plays’. One that stood out to us on Thursday morning was CNAB, and it enjoyed a respectable intraday performance subsequent to our premarket flag. We observed a low of .51 first thing in the morning, and the stock took off like a rocket. The high it shot up to was .75, marking a 47% rip.

The stock maintained a good portion of its daily advance into a close at .673, and of course volume was much higher than normal, so this is another that we’ll keep on our watchlist for the time being.


Cannabis Sativa, Inc. CBDS

Another run of success we’ve had recently within the cannabis sector has been due to our call of CBDS. We first introduced this stock to our reports in early February, and would monitor the stock as it found support at .30 several sessions later. From there it began a gradual rise that became much more pronounced midway through this month.

The gains on the chart since then have been absolutely stellar, and CBDS hasn’t looked back, as it recorded a new high of 3.73 on Thursday. That brought the overall upswing we’ve witnessed in just a month’s time to a meteoric 1143%


Another handful of marijuana stocks we’ve tracked over a long period of time are HEMP, TRTC, and GRNH, and those will continue to garner our attention in the immediate future, with interest in the sector bubbling up once again.

Extended Watchlist:

Blue Horseshoe Stocks: New Options Ideas & More

New Options Ideas

The market, which has been struggling mightily here in the opening weeks of 2016 for numerous reasons, appears to be in line for some measure of a rebound today, based on early trading activity. Q4 earnings season has kicked off, which should result in an increase of options trading opportunities in the days and weeks ahead.  In the event this trend holds and progresses, we’re going to want to have a few options contracts ready and waiting in the hopper to watch for swing-trade possibilities.

Shire plc SHPG

SHPG shares are gapping up to the tune of more than 5% in the premarket this morning in the wake of the revelation that Shire would be acquiring US-based Baxalta for a whopping $32B. The deal figures to create the largest rare-disease drugmaker conglomerate in the world.

We like to take advantage of blockbuster reveals such as this, and the trading hysteria they tend to create. For this particular situation, we are going to set our sights on SHPG Weekly $175-180 Calls.


Acadia Pharmaceuticals, Inc. ACAD

ACAD has been tumbling down in terms of PPS in recent sessions. The reported possibility of dilution as a result of fundraising via public offering has had investors coming down on the bearish side of the fence. We want to be on the lookout for the possibility of a rebound. If such a move occurs we’re going to have the ACAD 02/19 $29 Calls and 03/18 $30 Calls on our radars moving forward.

Alcoa, Inc. AA – Possible Recovery Play

AA is striking us as a stock whose time for a rebound may be fast approaching. We want to signal this as a potential bottom-play. The strength index is heading into heavily oversold territory, and a triple-bottom setup suggests AA could be nearing basement-level prices.

We’re going to add this to our current list of bottom-watch plays, which also includes KOOL, MGI, GNBT, and MAXD.

Extended Watchlist: